ALLIANCE FOR REGENERATIVE MEDICINE

Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products; FDA appropriations and staffing, specifically at CBER and OT; FDA oversight, including adaptive regulatory pathways for cell and gene therapies; Value-based payment legislation and related CMS regulations; Biologics regulation; Prescription Drug User Fee Act (PDUFA); Medicaid; Medicare; NIH appropriations; HHS oversight; HHS staffing and OPM issues; Federal support of medical research; Pharmaceutical tariffs; Biotechnology manufacturing.